Clinical Trial Update: Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers [Phase 2]

View source ↗

Summary

Update on a Phase 2 trial of lenvatinib plus pembrolizumab in advanced adenoid cystic carcinoma and other salivary gland cancers. The study status is ACTIVE_NOT…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma
• Salivary Gland Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Adenoid Cystic Carcinoma, Salivary Gland Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING